Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

Posted by James Quigley on Mar 30th, 2025

Stock analysts at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a note issued to investors on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

EVOK opened at $2.79 on Friday. The firm has a market cap of $4.17 million, a P/E ratio of -0.25 and a beta of 0.12. Evoke Pharma has a 52 week low of $2.50 and a 52 week high of $12.32. The business has a fifty day simple moving average of $4.25 and a 200-day simple moving average of $4.63.

Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). The business had revenue of $3.31 million during the quarter, compared to analysts’ expectations of $3.08 million. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC increased its stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) by 163.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 148,194 shares of the specialty pharmaceutical company’s stock after buying an additional 91,945 shares during the period. Nantahala Capital Management LLC owned about 9.95% of Evoke Pharma worth $655,000 as of its most recent filing with the Securities and Exchange Commission.

Evoke Pharma Company Profile

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.